The imaging division of Biomedical Systems, a global provider of centralized diagnostic services, has formed a collaboration with Massachusetts General Hospital (MGH) to evaluate the efficacy of new drugs and devices.
Biomedical Systems’ digital medical imaging technologies support clinical trials by capturing the body’s reaction to a new drug or device to determine its effectiveness. The images are then read by a radiologist, which historically Biomedical hand-selected based on the clinical trial criteria and expertise in the anatomical region or disease pathology.
MGH will provide Biomedical Systems with a dedicated reading room to expedite image reviews by hospital radiologists who review information from more than 200 clinical trials. The agreement allows Biomedical Systems and MGH’s radiology teams to meet aggressive deadlines while safeguarding the clinical trials’ accuracy.
“Our goal is to ensure that the information we provide when reviewing images is not only timely, but most importantly, accurate,” said Amy Corbosiero, manager of drug trials operations in MGH Imaging. “It is especially important in clinical trials that variability is low. It is in all of our best interests to make sure that the most accurate clinical data is factored into studies that determine which drugs and devices will one day be available to the patients we serve.”
Biomedical’s collaboration with MGH is not exclusive, and allows the company to work with specialty radiologists around the world as dictated by the clinical trial.
“Our job is to help drug and medical device developers determine if their health innovation meets its intended objectives,” said Jeffrey Bowden, president, imaging services, Biomedical Systems. “It’s critical for our clients to know they have access to superior imaging technology and the industry’s most revered radiologists so they can trust the data and meet their critical timelines. Our collaboration with MGH ensures our images will be read by expert radiologist professionals at any time—evenings or weekends when needed. Still, we have the freedom to partner with other specialty radiologists when warranted and remain dedicated to working and innovating with relevant medical industries.”
